Top

15-01-2016 | Nausea and vomiting | Review | Article

Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis

Journal: Supportive Care in Cancer

Authors: Leonard Chiu, Ronald Chow, Marko Popovic, Rudolph M. Navari, Nathan M. Shumway, Nicholas Chiu, Henry Lam, Milica Milakovic, Mark Pasetka, Sherlyn Vuong, Edward Chow, Carlo DeAngelis

Publisher: Springer Berlin Heidelberg

Abstract

Purpose

Olanzapine is a potent antipsychotic medication that inhibits a wide variety of receptors. It has been used in trials for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV). This study systematically investigates the efficacy of olanzapine in relation to other antiemetics in the prophylaxis and rescue of CINV.

Methods

A literature search of Ovid MEDLINE, EMBASE, and CENTRAL was conducted to identify randomized controlled trials (RCTs) comparing olanzapine to other standard antiemetics for either prevention or rescue. The primary endpoints were the percentage of patients achieving no emesis or no nausea, in the acute, delayed, and overall phases.

Results

Ten RCTs in the preventative setting and three RCTs in the breakthrough setting were identified. Subgroup analysis demonstrated a similar degree of benefit from a 5- and 10-mg dose of olanzapine for the no emesis endpoint in the overall phase. In the prophylaxis setting, olanzapine was statistically superior in five of six endpoints and clinically superior in four of six endpoints. In the breakthrough setting, olanzapine was statistically and clinically superior in the only endpoint analyzed: no emesis.

Conclusion

Olanzapine is more efficacious than other standard antiemetics for the rescue of CINV and its inclusion improves control in the prevention setting. Given the possible reduction in side effects, the use of a 5-mg dose of olanzapine should be considered. Future RCTs should compare the 5-mg versus the 10-mg dosages further and report on the efficacy and percentage of patients developing side effects. Further analyses should be done without the influence of corticosteroids.

Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5(4):307–313CrossRefPubMed

Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetic American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–98CrossRefPubMedPubMedCentral

Hocking CM, Kichenadasse G (2014) Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer 22(4):1143–1151CrossRefPubMed

Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R (2003) Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manag 25(6):578–582CrossRef

Navari RM, Einhorn LH, Passik SD, Loehrer PJ, Johnson C, Mayer ML et al (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer 13(7):529–534CrossRefPubMed

Passik SD, Navari RM, Jung SH, Nagy C, Vinson J, Kirsh KL et al (2004) A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Investig 22(3):383–388CrossRef

Passik SD, Kirsh KL, Theobald DE, Dickerson P, Trowbridge R, Gray D et al (2003) A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manag 25(5):485–488CrossRef

Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E et al (2002) A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manag 23(6):526–532CrossRef

Navari RM, Einhorn LH, Loehrer PJ, Passik SD, Vinson J, McClean J et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 15(11):1285–1291CrossRefPubMed

10.

Chanthawong S, Subongkot S, Sookprasert A (2014) Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting. J Med Assoc Thail = Chotmaihet Thangphaet 97(3):349–355

11.

Tan L, Liu J, Liu X, Chen J, Yan Z, Yang H, Zhang D (2009) Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:131CrossRefPubMedPubMedCentral

12.

Shumway NM, Terrazzino SE, Jones CB (2009) A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting. J Clin Oncol: Ann ASCO Meet 27(15)

13.

Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21(6):1655–1663CrossRefPubMed

14.

Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9(5):188–195CrossRefPubMed

15.

Navari RM, Gray SE (2009) Treatment of chemotherapy-induced breakthrough nausea and vomiting. Conference publication: 2009 annual meeting of the American Society of Clinical Oncology

16.

Mizukami N, Yamauchi M, Koike K, Watanabe A, Ichihara K, Masumori N et al (2014) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manag 47(3):542–550CrossRef

17.

Wang X, Wang L (2012) Effectiveness of olanzapine in prevention of chemotherapy induced nausea and vomiting. Clin J Clin (Electron Ed) 6:7406–7407

18.

Mao WK, Peng L (2011) Clinical observation of Olanzapine combined with Granisetrom and Hexadecadrol prevent nausea vomit induced by chemoradiotherapy. Chin J Med Guid 13:452–454

19.

Lu YL et al (2013) Antiemetic effect of low dose olanzapine in solid tumor chemotherapy. Clin J Cancer Prev Treat 20:544–554

20.

Navari RM, Gray S (2010) Treatment of chemotherapy-induced breakthrough nausea and vomiting. Conference publication: 7th annual conference of the American Psychosocial Oncology Society

21.

Navari RM, Nagy CK (2015) Olanzapine versus fosaprepitant for the prevention of nausea and vomiting in patients receiving concurrent chemo-radiation treatment. Conference publication: 2015 annual meeting of the American Society of Clinical Oncology

22.

Mukhopadhyay S, Kwartra G, Jeyaraj P, Badyal D (2015) Role of olanzapine in chemotherapy induced nausea and vomiting on platinum based chemotherapy patients: a randomized controlled study. Conference publication: MASCC/ISOO Annual Meeting on Supportive Care in Cancer

23.

Wang X, Wang L, Wang H, Zhang H (2015) Effectiveness of olanzapine combined with ondansetron in prevention of chemotherapy-induced nausea and vomiting of non-small cell lung cancer. Cell Biochem Biophys 1–3

24.

Wang XF, Feng Y, Chen Y, Gao BL, Han BH (2014) A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Sci Rep 4:4813PubMedPubMedCentral

25.

Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243CrossRefPubMed

26.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study G (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090–3098CrossRefPubMed

27.

Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17(6):1000–1006CrossRefPubMed

28.

Aapro M, Rossi G, Rizzi G, Palmas M, Grunberg S (2013) Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy induced nausea and vomiting (CINV) following moderately emetic chemotherapy (MEC). 2013 ASCO Annual Meeting Abstract LBA9514. Presented June 1st 2013

29.

Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497–503CrossRefPubMed

30.

Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B et al (2012) Antiemesis. J Natl Compr Cancer Netw 10(4):456–485

31.

Bymaster FP, Calligaro D, Falcone J et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87–96CrossRefPubMed

32.

Fonte C, Fatigoni S, Roila F (2015) A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients. Crit Rev Oncol/Hematol 95(2):214–221CrossRef

33.

Kane J, Stefan L, Carpenter D, Docherty J (2003) Introduction: methods, commentary, and summary. J Clin Psychiatr 64(suppl 12):5–19

34.

Nemeroff CB (1997) Dosing the antipsychotic medication olanzapine. J Clin Psychiatr 58(suppl 10):45–9

35.

Hale AS (1997) Olanzapine. Br J Hosp Med 58:443–445

36.

Detke H, McDonnell D, Brunner E et al (2010) Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry 10:43CrossRefPubMedPubMedCentral

37.

Battaglia J, Lindborg S, Alaka K et al (2003) Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 21(3):192–198CrossRefPubMed

38.

National Comprehensive Cancer Network (2014) NCCN guidelines version 1.2014 www.nccn.org. Accessed 7 July 2015